SCHAUMBURG, Ill., March 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefepime for injection, USP, a broad ...
More than 2 weeks of treatment with cefepime administered by intravenous (IV) push significantly increases the risk of cefepime-induced neutropenia. A new study has demonstrated that prolonged courses ...
Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor ...
Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results